TY - JOUR
T1 - RNA-Seq of Circulating Tumor Cells in Stage II–III Breast Cancer
AU - Lang, Julie E.
AU - Ring, Alexander
AU - Porras, Tania
AU - Kaur, Pushpinder
AU - Forte, Victoria A.
AU - Mineyev, Neal
AU - Tripathy, Debu
AU - Press, Michael F.
AU - Campo, Daniel
N1 - Funding Information:
This project was supported by a Society of Surgical Oncology Clinical Investigator Award, a California Breast Cancer Research Program IDEA award, and a STOP Cancer Marni Levine Memorial Seed Grant (JL). The project was also supported in part by grant UL1TR001855 from the National Center for Advancing Translational Science (NCATS) and grant P30CA014089 from the National Cancer Institute of the US National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Magnetic cell separators were kindly made by the laboratory of Maciej Zborowski (Cleveland Clinic) based on the design provided by BD Biosciences. Julie E. Lang and Alexander Ring served as co-first authors.
Funding Information:
ACKNOWLEDGEMENT This project was supported by a Society of Surgical Oncology Clinical Investigator Award, a California Breast Cancer Research Program IDEA award, and a STOP Cancer Marni Levine Memorial Seed Grant (JL). The project was also supported in part by grant UL1TR001855 from the National Center for Advancing Translational Science (NCATS) and grant P30CA014089 from the National Cancer Institute of the US National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Magnetic cell separators were kindly made by the laboratory of Maciej Zborowski (Cleveland Clinic) based on the design provided by BD Biosciences.
Publisher Copyright:
© 2018, Society of Surgical Oncology.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Background: We characterized the whole transcriptome of circulating tumor cells (CTCs) in stage II–III breast cancer to evaluate correlations with primary tumor biology. Methods: CTCs were isolated from peripheral blood (PB) via immunomagnetic enrichment followed by fluorescence-activated cell sorting (IE/FACS). CTCs, PB, and fresh tumors were profiled using RNA-seq. Formalin-fixed, paraffin-embedded (FFPE) tumors were subjected to RNA-seq and NanoString PAM50 assays with risk of recurrence (ROR) scores. Results: CTCs were detected in 29/33 (88%) patients. We selected 21 cases to attempt RNA-seq (median number of CTCs = 9). Sixteen CTC samples yielded results that passed quality-control metrics, and these samples had a median of 4,311,255 uniquely mapped reads (less than PB or tumors). Intrinsic subtype predicted by comparing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) versus PAM50 for FFPE tumors was 85% concordant. However, CTC RNA-seq subtype assessed by the PAM50 classification genes was highly discordant, both with the subtype predicted by ER/PR/HER2 and by PAM50 tumors. Two patients died of metastatic disease, both of whom had high ROR scores and high CTC counts. We identified significant genes, canonical pathways, upstream regulators, and molecular interaction networks comparing CTCs by various clinical factors. We also identified a 75-gene signature with highest expression in CTCs and tumors taken together that was prognostic in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium datasets. Conclusion: It is feasible to use RNA-seq of CTCs in non-metastatic patients to discover novel tumor biology characteristics.
AB - Background: We characterized the whole transcriptome of circulating tumor cells (CTCs) in stage II–III breast cancer to evaluate correlations with primary tumor biology. Methods: CTCs were isolated from peripheral blood (PB) via immunomagnetic enrichment followed by fluorescence-activated cell sorting (IE/FACS). CTCs, PB, and fresh tumors were profiled using RNA-seq. Formalin-fixed, paraffin-embedded (FFPE) tumors were subjected to RNA-seq and NanoString PAM50 assays with risk of recurrence (ROR) scores. Results: CTCs were detected in 29/33 (88%) patients. We selected 21 cases to attempt RNA-seq (median number of CTCs = 9). Sixteen CTC samples yielded results that passed quality-control metrics, and these samples had a median of 4,311,255 uniquely mapped reads (less than PB or tumors). Intrinsic subtype predicted by comparing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) versus PAM50 for FFPE tumors was 85% concordant. However, CTC RNA-seq subtype assessed by the PAM50 classification genes was highly discordant, both with the subtype predicted by ER/PR/HER2 and by PAM50 tumors. Two patients died of metastatic disease, both of whom had high ROR scores and high CTC counts. We identified significant genes, canonical pathways, upstream regulators, and molecular interaction networks comparing CTCs by various clinical factors. We also identified a 75-gene signature with highest expression in CTCs and tumors taken together that was prognostic in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium datasets. Conclusion: It is feasible to use RNA-seq of CTCs in non-metastatic patients to discover novel tumor biology characteristics.
UR - http://www.scopus.com/inward/record.url?scp=85048021220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048021220&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-6540-4
DO - 10.1245/s10434-018-6540-4
M3 - Article
C2 - 29868978
AN - SCOPUS:85048021220
SN - 1068-9265
VL - 25
SP - 2261
EP - 2270
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 8
ER -